Woodland Bioscience, Inc. Prevents Pre-clinical Research Slow Downs – Relocates and Expands with a Privately Owned Vivarium in Syracuse, NY.

Share Article

Woodland Biosciences, Inc. doubles capacity with new 5,500 RSF state-of-the-art vivarium research space, complete with professional animal care technicians, surgical veterinary staff, and IACUC oversight. Operating as a contract research organization with expertise in new model generation for fibrosis, oncology, and aging, Woodland Bio's leadership recognized the impact Covid shutdowns have had on early pre-clinical research. Fully operational in central New York, Woodland's unique metabolic disease (NASH, CCL4, TAA) in vivo models and in vitro spheroid screening platforms are ready for business.

This transition will allow Woodland BIO to stabilize research impacted by COVID to maintain client studies if their main research labs are impacted." Dr. Michael Briggs, CSO

Woodland Biosciences, Inc., a pre-clinical contract research organization, announced today an expansion of its facilities and service offerings as part of a corporate restructuring.

The company will now occupy newly renovated commercial facilities in LaFayette, NY, which include maximum barrier small animal and large animal housing and wet labs. Additional PhD-level scientists and a full-time veterinary surgeon will join the ranks of Woodland to support the company’s growing list of clients, providing additional talent in histology/immunohistochemistry, flow cytometry, cellular assays, and in vivo surgical models to augment its expertise in metabolic diseases including liver fibrosis and cancer biology, including immune-oncology, orthotopic models and PDX. Coupled with the expanded in-house capabilities, local resources will enable PK/PD modeling and drug discovery support from protein structure through cell and animal studies.

Dr. Mike Briggs, Founder, President and CSO of Woodland, stated, “This transition will allow us to stabilize research impacted by COVID to maintain client studies if their main research labs are impacted, while bringing critical assets and competencies in-house. A top 5 pharma in the Boston area closed its research labs and terminated all in vivo experiments causing irreparable damage to their early pipeline, and many University labs across the U.S. also had to shut down all in vivo studies. As an essential business in New York, our site has remained open since the beginning of the pandemic.” Dr. Briggs further noted, “A strong pipeline of talented scientists / technicians and access to university core infrastructure is available through nearby universities Cornell, Syracuse, SUNY Upstate, and SUNY ESF. Collectively, our additional services and scale will position Woodland to better support its client base with the depth of expertise and capabilities that have come to define our brand.”

Dr. Kelsey Moody will join Woodland as interim CEO. “For the last decade Woodland has been a powerhouse in fibrosis, metabolic disease, and oncology,” said Moody. “They have supported numerous IND applications and invest heavily in intramural research to continuously re-define best-in-class models. This is a philosophy that I share and I look forward to helping the company continue to accelerate drug development for our clients.”

Press inquiries should be directed to Michele Nathan Borek at info@woodlandbiosciences.com.

About Woodland:
Woodland Biosciences, Inc. is a pre-clinical contract research organization with expansive expertise in fibrosis, metabolic disease, and oncology. Key to our company ethos is a dedication to providing clients with the most clinically relevant models available to accelerate drug development. Founded by pharmaceutical company executives with deep foundations in translational science, we offer smart, innovative, and unparalleled services to our diverse client base.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Laura Sailor
Visit website